We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreWe compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...
Read moreAccording to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...
Read moreAn affordable and sustainable market access landscape is key to ensure patient access to life-saving...
Read moreWe explore why combination pricing is an issue in the oncology space and why payers and manufacturer...
Read moreThe National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...
Read moreThe CDF allows patients to access a new treatment while further data is collected on its clinical an...
Read moreIn a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...
Read moreCell and gene therapies - life saving opportunity for many patients
Read more